Human interferon beta
Also known as: Avonex, Betaseron, Extavia, IFN-beta-1a, IFN-beta-1b, IFN-β, Interferon beta-1a, Interferon beta-1b, Rebif
Source Human interferon beta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Human interferon beta (IFN‑β) is a type I cytokine approved as a prescription medicine for the treatment of multiple sclerosis. Delivered by injection, it exerts antiviral, immunomodulatory and anti‑proliferative actions, helping to slow disease progression in patients with this autoimmune disorder.
Mechanism of Action
IFN‑β binds the heterodimeric type I interferon receptor (IFNAR1/IFNAR2) on cell surfaces, triggering JAK‑STAT signaling that induces expression of interferon‑stimulated genes. These genes mediate antiviral defenses, modulate innate and adaptive immune responses, and inhibit cell proliferation. Structural studies show that glycosylation of IFN‑β contributes to its solubility, stability and receptor interaction, distinguishing its activity from other IFN‑I subtypes.
What the Research Shows
Early work identified IFN‑β as an antiviral protein, later revealing broader immune‑regulating functions. A 1998 structural analysis highlighted the importance of its unique glycosylation for stability and activity. A 2021 review compared IFN‑β with IFN‑α subtypes, noting shared receptor use but distinct biological effects, and reaffirmed its therapeutic role in chronic viral infections and multiple sclerosis. A 2016 study addressed the immunogenicity of IFN‑β products, developing a reporter cell assay to quantify neutralizing antibodies in multiple sclerosis patients, underscoring the clinical relevance of anti‑drug antibodies.
Reported Benefits
Clinical use of IFN‑β in multiple sclerosis has been shown to retard disease progression, likely through modulation of inflammatory pathways. Laboratory data confirm its antiviral potency and ability to suppress cancer cell proliferation. The cytokine’s capacity to shape both innate and adaptive immunity supports its role in managing chronic viral infections and autoimmune activity.
Limitations of the Evidence
A key limitation is the development of neutralizing antibodies in some patients, which can diminish therapeutic efficacy. Structural differences among IFN‑I family members mean that activity can vary, and the precise reasons for the diversity of IFN‑β effects remain incompletely understood. Evidence for anti‑cancer benefits is largely pre‑clinical, and broader clinical data are limited.
Safety Considerations
While specific adverse events are not detailed in the cited abstracts, the formation of neutralizing antibodies against IFN‑β is a recognized safety concern that can reduce drug effectiveness. Monitoring antibody levels may be necessary in long‑term therapy. No other safety signals are reported in the available literature.
How It Is Administered
Human interferon beta is administered by injection, typically via intramuscular or subcutaneous routes. Commercial preparations are formulated for these parenteral deliveries, allowing systemic exposure to achieve the desired immunomodulatory effects.
Routes of Administration
Goals & Uses
- Reduce relapse rate in RRMSEfficacyHigh
- Reduction of relapse rate in relapsing-remitting multiple sclerosisDisease ModificationHigh
- Delay of disability progression in MSNeurological / AutoimmuneHigh
- Clinically isolated syndrome (CIS) — delay to clinically definite MSNeurological / AutoimmuneHigh
- Antiviral activityInfectious DiseaseModerate
- Delay disability progressionEfficacyHigh
- Reduction of MRI lesion burdenNeurological / AutoimmuneHigh
Contraindications
- Pregnancy (especially IFN-β-1b)ReproductiveModerate
- Decompensated hepatic diseaseHepaticHigh
- Hypersensitivity to IFN‑β or excipientsAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Severe depressive disorder with suicidal ideationPsychiatricHigh
- Severe depression or suicidal ideationPsychiatricModerate
- Hypersensitivity to natural or recombinant interferon beta or any excipientAllergy / ImmunologyHigh
Adverse Effects
- Hepatotoxicity / elevated liver enzymesHepaticCommon
- LeukopeniaHematologicRareLow white blood cell count
- Injection site reactionsLocalCommon
- Flu‑like syndromeSystemicCommon
- Hematological abnormalities (leukopenia, thrombocytopenia, anemia)HematologicalUncommon
- Flu-like symptoms (fever, chills, myalgia, fatigue)Systemic / ConstitutionalCommon
- Depression and suicidal ideationPsychiatricUncommon
- DepressionPsychiatricUncommon
- Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
- Neutralizing antibodies (NAbs)ImmunologicalCommon
Drug Interactions
- Immunosuppressants (e.g., azathioprine)Moderate
- Myelosuppressive agentsModerate
- Immunosuppressants (e.g., corticosteroids)Low
- Live vaccinesHigh
- CYP450 substrates (e.g., warfarin, phenytoin)Low
- CorticosteroidsModerate
- Hepatotoxic drugs (e.g., methotrexate, azathioprine, statins)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pre-existing severe psychiatric disordersPsychiatricRelative
- LactationReproductiveRelative
- Pediatric patients (<18)AgeRelative
- Pediatric patients (<12 years)PediatricRelative
- Pregnant womenReproductiveRelative
- Elderly (>65)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Relapsing‑remitting multiple sclerosisEMA approval; several biosimilars authorized
- United StatesApprovedApproved: Relapsing‑remitting multiple sclerosis, Clinically isolated syndromeMultiple formulations (Avonex, Rebif, Betaseron, Extavia) approved by FDA
- United KingdomApprovedApproved: Relapsing‑remitting multiple sclerosisMHRA approved
Approved in US, EU, and UK for multiple sclerosis; several biosimilar versions are available.
Evidence & Sources
- Journal ArticleModerateSehgal PB, May LT1987-01-01T00:00:00.000000Z
- Journal ArticleModerateNazarov VD, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateWittling MC, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateKarpusas M, et al.1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is interferon beta officially approved to treat?
Interferon beta is an approved prescription therapy for multiple sclerosis, where it helps slow disease progression by modulating immune activity.
How does interferon beta work at the cellular level?
It binds the IFNAR1/IFNAR2 receptor complex, activating JAK‑STAT signaling that induces genes responsible for antiviral defenses, immune regulation, and inhibition of cell growth.
Can patients develop resistance to interferon beta?
Yes, some patients generate neutralizing antibodies that bind the drug and reduce its biological activity, potentially limiting therapeutic benefit.
Is interferon beta used for infections or cancer?
Laboratory studies show antiviral and anti‑proliferative properties, and it is investigated for chronic viral infections and cancer, but clinical approval is currently limited to multiple sclerosis.
What routes of administration are available for interferon beta?
The drug is formulated for injection, delivered either intramuscularly or subcutaneously, providing systemic exposure.
What is Human interferon beta?
Human interferon beta (IFN‑β) is a type I cytokine approved as a prescription medicine for the treatment of multiple sclerosis. Delivered by injection, it exerts antiviral, immunomodulatory and anti‑proliferative actions, helping to slow disease progression in patients with this autoimmune disorder.
What is Human interferon beta used for?
Human interferon beta is educationally associated with: Reduce relapse rate in RRMS, Reduction of relapse rate in relapsing-remitting multiple sclerosis, Delay of disability progression in MS, Clinically isolated syndrome (CIS) — delay to clinically definite MS, Antiviral activity, Delay disability progression, Reduction of MRI lesion burden. Educational only — not medical advice.
How is Human interferon beta administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Human interferon beta?
Reported adverse effects include: Hepatotoxicity / elevated liver enzymes, Leukopenia, Injection site reactions, Flu‑like syndrome, Hematological abnormalities (leukopenia, thrombocytopenia, anemia), Flu-like symptoms (fever, chills, myalgia, fatigue), Depression and suicidal ideation, Depression, Elevated liver enzymes, Neutralizing antibodies (NAbs). This list is not exhaustive — consult a qualified clinician.
Who should avoid Human interferon beta?
Recorded contraindications: Pregnancy (especially IFN-β-1b), Decompensated hepatic disease, Hypersensitivity to IFN‑β or excipients, Pregnancy, Severe depressive disorder with suicidal ideation, Severe depression or suicidal ideation, Hypersensitivity to natural or recombinant interferon beta or any excipient. Consult a qualified clinician before use.